HC Wainwright Reaffirms Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO)

HC Wainwright reiterated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note published on Friday,Benzinga reports.

Xenetic Biosciences Trading Down 1.6 %

Shares of XBIO stock opened at $4.04 on Friday. The company has a market capitalization of $6.22 million, a P/E ratio of -1.52 and a beta of 2.25. The business’s 50 day moving average is $3.91 and its two-hundred day moving average is $3.92. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. As a group, equities analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.